Jason Mouabbi, MD

Dr. Jason Mouabbi and Dr. Ruta Rao discuss balancing the efficacy of T-DXd with safety considerations in the treatment of HER2-positive early breast cancer, with particular emphasis on interstitial lung disease (ILD) in the curative setting.

Dr. Jason Mouabbi discusses the evolving roles of T-DXd and T-DM1 in the post-neoadjuvant management of HER2-positive early breast cancer following the DESTINY-Breast05 findings.

Dr. Jason Mouabbi discusses the design and patient population of DESTINY-Breast05 in the post-neoadjuvant setting for HER2-positive early breast cancer, highlighting key distinctions from the broader KATHERINE study population.

Dr. Jason Mouabbi discusses how the broader FDA neoadjuvant indication for HER2-positive early breast cancer may be interpreted in clinical practice relative to the more narrowly defined high-risk population enrolled in DESTINY-Breast11.

Dr. Ruta Rao reviews the design and key findings of DESTINY-Breast11 in patients with high-risk HER2-positive early breast cancer receiving neoadjuvant therapy.

Experts unpack evolving neoadjuvant and adjuvant strategies for high‑risk HER2+ early breast cancer, from TCHP to T-DM1, T-DXd, and neratinib.

Dr. Jason Mouabbi and Dr. Seth Wander discuss future opportunities to refine biomarker-driven treatment approaches for patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss evolving questions surrounding the implementation of biomarker-guided treatment strategies in HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss practical considerations for integrating molecular testing approaches into routine care for patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss real-world considerations for incorporating molecular monitoring strategies into the management of HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss the practical considerations surrounding the use of ctDNA monitoring in patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Seth Wander and Dr. Jason Mouabbi discuss the potential significance of circulating tumor DNA clearance as a marker of treatment response in HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss the evolving role of circulating tumor DNA dynamics as a potential tool for evaluating treatment response in HR-positive, HER2-negative advanced breast cancer.

Dr. Seth Wander and Dr. Jason Mouabbi discuss the importance of evaluating both clinical outcomes and patient experience when selecting treatment strategies for HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss emerging evidence evaluating proactive treatment strategies for patients with HR-positive, HER2-negative advanced breast cancer with ESR1 mutations.

Dr. Jason Mouabbi and Dr. Seth Wander discuss the clinical rationale for identifying and addressing ESR1-mediated endocrine resistance earlier in patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss treatment considerations for patients with HR-positive, HER2-negative advanced breast cancer who develop ESR1 mutations following first-line endocrine therapy and CDK4/6 inhibition.

Dr. Jason Mouabbi and Dr. Seth Wander discuss current approaches to biomarker testing and ESR1 mutation detection in patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss the biological role of ESR1 mutations and their impact on endocrine resistance in HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss considerations for treatment selection following first-line therapy in HR-positive, HER2-negative advanced breast cancer, highlighting the evolving definition of endocrine sensitivity and the growing role of precision medicine. Dr. Wander explains how the availability of newer endocrine-based therapies and targeted treatment approaches has expanded options for patients who experience disease progression. The discussion explores how molecular alterations, including ESR1 mutations, PIK3CA mutations, AKT pathway alterations, and other biomarkers, can influence treatment selection in the second-line setting. Dr. Wander also emphasizes ongoing challenges in patients without actionable alterations or those with multiple concurrent resistance mechanisms, highlighting the need for continued research to better guide sequencing strategies. The experts underscore the increasing complexity of treatment decisions as the field moves toward more individualized approaches for patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander open the discussion by reviewing the evolving treatment landscape for patients with HR-positive, HER2-negative advanced breast cancer. Dr. Wander discusses the role of endocrine therapy combined with CDK4/6 inhibition as a foundational first-line treatment approach, while highlighting important patient-specific considerations such as endocrine sensitivity, prior therapy exposure, and the emergence of targeted treatment strategies. The experts discuss how advances in earlier-line therapy have improved outcomes for many patients while also contributing to an increasingly complex treatment landscape. Dr. Mouabbi emphasizes the significant impact of CDK4/6 inhibitors in transforming the management of HR-positive, HER2-negative advanced breast cancer and highlights the importance of optimizing endocrine-based treatment strategies as resistance mechanisms emerge. The discussion sets the foundation for exploring biomarker-driven approaches, including strategies aimed at addressing evolving endocrine resistance.

Explore oral treatment choices after CDK4/6 progression in ER+ metastatic breast cancer, using ESR1/PIK3CA ctDNA plus scans and markers to track response.

New data highlight oral SERD combination therapies boosting progression-free survival, while raising toxicity and reshaping when ESR1 mutation testing guides treatment choices.

Experts compare oral SERDs’ side effects, quality-of-life gains, and why brief ESR1 testing delays help choose smarter ER+ breast cancer therapy.

Expert guidance on post-CDK4/6 metastatic breast cancer care, using liquid biopsy mutations to tailor oral SERDs versus targeted doublets for best outcomes.

Oral SERDs transform metastatic breast cancer care, with elacestrant boosting outcomes in ESR1-mutant disease and showing strong real-world progression-free survival.

Why ESR1 mutations rise after CDK4/6 therapy, when to retest via liquid biopsy, and how low VAF still guides SERD choices.

Experts discuss the potential of antibody-drug conjugates in treating triple-negative breast cancer, highlighting ongoing trials and emerging therapies.

Experts discuss the critical unmet needs in triple-negative breast cancer, highlighting innovative treatments and the importance of developing effective biomarkers.

Explore effective strategies for managing side effects of ADC therapy in triple-negative breast cancer, focusing on toxicity and patient care.